leadf
logo-loader
RNS
viewTissue Regenix Group PLC

Tissue Regenix Group - Notice of Interim Results & Investor Presentation

RNS Number : 2631X
Tissue Regenix Group PLC
27 August 2020
 

Tissue Regenix Group plc

Notice of Interim Results and Investor Presentation

Leeds, 27 August 2020 - Tissue Regenix Group (AIM:TRX) (the "Company") the regenerative medical devices company today gives notice that it will announce its unaudited interim results for the six months ending 30th June 2020, on Wednesday 2nd  September 2020.

The Company is committed to ensuring that there are appropriate communication structures for all elements of its shareholder base and will provide a live investor presentation relating to the 2020 interim results, via the Investor Meet Company platform, on Thursday 3rd September at 17:00.

This presentation is open to all existing and potential investors. Questions can be submitted prior to the event or any time during the live presentation via the "Ask a Question" function.

Investors can sign up to the Investor Meet Company for free and attend this presentation via the below link:

https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor

Investors who have already registered to meet the Company, will be automatically invited to the meeting.

 

 

 

For more Information:

 

Tissue Regenix Group plc

Caitlin Pearson                                 Head of Communications  

 

            Tel: 0330 430 3073

 

 

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Ben Maddison / Alex Price

             Tel:  0207 710 7600

 

 


FTI Consulting 

Simon Conway / Victoria Foster Mitchell / Mary Whittow

Tel: 0203 727 1000

 

 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

 

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOREAEPKADAEEAA

Quick facts: Tissue Regenix Group PLC

Price: 0.37

Market: AIM
Market Cap: £26.02 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

3 min read